ESBATech initiates Phase IIa uveitis trial

This study is designed to evaluate the safety, tolerability and clinical activity of topically applied ESBA105 in uveitis patients. ESBA105 is a single-chain antibody fragment directed against TNF-alpha, a major mediator of inflammation. The Phase IIa trial is being conducted at several uveitis centers in Germany.

The primary objectives of this study are to assess the local tolerability and safety of topical ESBA105, as well as to evaluate the clinical activity of patients suffering from an attack of acute, unilateral anterior uveitis.

With this Phase IIa study in uveitis and recently announced Phase Ib/IIa study in patients undergoing cataract surgery, the company said that it continues to advance a pipeline of novel, antibody fragment therapeutics for local delivery in ocular diseases to ensure safe and convenient patient therapy.

In conjunction with the Phase IIa uveitis study, ESBATech has established a clinical advisory board dedicated to the advancement of the company’s uveitis clinical development.

Dominik Escher, CEO of ESBATech, said: The newly established uveitis clinical advisory board, which consists of distinguished and well-respected leaders in the ophthalmology field, will be of great strategic value as we advance ESBA105 through clinical development for uveitis. With our advisory board in place and the continued clinical progression in uveitis and other inflammatory ocular diseases, the company is well positioned to become the leader in delivering antibody fragments to both the anterior and posterior segment of the eye.